½ÃÀ庸°í¼­
»óǰÄÚµå
1543907

¼¼°èÀÇ Á¾¾ç ÀýÁ¦ ±â¼ú ½ÃÀå

Tumor Ablation Technologies

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Industry Analysts, Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 196 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Á¾¾ç ÀýÁ¦ ±â¼ú ¼¼°è ½ÃÀå, 2030³â±îÁö 38¾ï ´Þ·¯ ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á

2023³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Á¾¾ç ÀýÁ¦ ±â¼ú ¼¼°è ½ÃÀåÀº 2023-2030³â ºÐ¼® ±â°£ µ¿¾È ¿¬Æò±Õ 13.3% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 38¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °íÁÖÆÄ ÀýÁ¦¼úÀº CAGR 13.7%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 14¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¶ÀÌÅ©·ÎÆÄ ÀýÁ¦ ºÎ¹®Àº ºÐ¼® ±â°£ µ¿¾È CAGR 14.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 2,960¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, Áß±¹Àº CAGR 12.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ÀÇ Á¾¾ç ÀýÁ¦ ±â¼ú ½ÃÀåÀº 2023³â 4¾ï 2,960¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2023-2030³â ºÐ¼® ±â°£ µ¿¾È 12.3%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 5¾ï 7,420¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 12.0%¿Í 11.0%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¾à 9.5%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è Á¾¾ç ÀýÁ¦ ±â¼ú ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

Á¾¾ç ÀýÁ¦¼úÀ̶õ ¹«¾ùÀ̸ç, ¿Ö Áß¿äÇѰ¡?

Á¾¾ç ÀýÁ¦¼úÀº ±ØÇÑÀÇ ¿­À̳ª ³Ã±â, Àü±â ¿¡³ÊÁö ¶Ç´Â È­ÇÐ ¾àǰÀ» »ç¿ëÇÏ¿© ¾Ï Á¶Á÷À» ÆÄ±«ÇÏ´Â µ¥ »ç¿ëµÇ´Â ÃÖ¼Òħ½ÀÀû Ä¡·á¹ýÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú¿¡´Â ¹æ»ç¼± ¼ÒÀÛ¼ú(RFA), ¸¶ÀÌÅ©·ÎÆÄ ¼ÒÀÛ¼ú, ³Ãµ¿ ¼ÒÀÛ¼ú, È­ÇÐÀû ¼ÒÀÛ¼ú µîÀÌ Æ÷ÇԵ˴ϴÙ. Á¾¾ç ¼ÒÀÛ¼úÀº °£, ½ÅÀå, Æó, »À¿Í °°Àº Àå±â¿¡ ±¹ÇÑµÈ Á¾¾çÀ» Ä¡·áÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ±âÁ¸ÀÇ ¼ö¼úÀû ¹æ¹ýÀ» ´ëüÇÒ ¼ö ÀÖ´Â Ä¡·á¹ýÀÔ´Ï´Ù. ÀÌ ±â¼úÀº ȸº¹ ½Ã°£ ´ÜÃà, ÃÖ¼Òħ½À¼º, Á¾¾çÀ» Á¤È®ÇÏ°Ô Ç¥ÀûÈ­ÇÒ ¼ö ÀÖ´Â ´É·Â µî Å« ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. Á¾¾ç ÀýÁ¦¼úÀº ¼ö¼úÀÌ ÀûÇÕÇÏÁö ¾Ê°Å³ª Á¢±ÙÇϱ⠾î·Á¿î À§Ä¡¿¡ Á¾¾çÀÌ Àִ ȯÀÚ¿¡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô ½ÃÀåÀ» Çü¼ºÇØ ¿Ô½À´Ï±î?

±â¼úÀÇ ¹ßÀüÀº Á¾¾ç ÀýÁ¦ ±â¼úÀÇ °³¹ß°ú ÀÀ¿ë¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÃÊÀ½ÆÄ, CT, MRI¿Í °°Àº ¿µ»ó Áø´Ü ±â¼úÀÇ Çõ½ÅÀº ÀýÁ¦¼úÀÇ Á¤È®¼º°ú ÁöħÀ» Çâ»ó½ÃÄÑ Á¾¾çÀ» º¸´Ù Á¤È®ÇÏ°Ô Ç¥ÀûÈ­ÇÒ ¼ö ÀÖ°Ô Çß½À´Ï´Ù. ¿¡³ÊÁö Àü´Þ ½Ã½ºÅÛÀ» °­È­ÇÑ Ã·´Ü ÀýÁ¦ ÀåºñÀÇ °³¹ßÀº ÀýÁ¦ Ä¡·áÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀ» Çâ»ó½Ã۰í ÇÕº´Áõ À§ÇèÀ» ÁÙÀ̸ç ȯÀÚ °á°ú¸¦ °³¼±Çß½À´Ï´Ù. Ä«Å×ÅÍ¿Í ÇÁ·Îºê ¼³°èÀÇ ¹ßÀüÀ¸·Î ÀýÁ¦ ±â¼úÀÇ »ç¿ë ÆíÀǼº°ú ¹ü¿ë¼ºÀÌ Çâ»óµÇ¾î ´õ ³ÐÀº ÀÓ»ó ÇöÀå¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ½Ç½Ã°£ ¸ð´ÏÅ͸µ ¹× Çǵå¹é ½Ã½ºÅÛÀÇ ÅëÇÕÀ¸·Î ÀýÁ¦¼úÀÇ Á¦¾î¿Í È¿°ú°¡ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº Á¾¾ç ÀýÁ¦ ±â¼úÀÇ ¿ëµµ¿Í È¿´ÉÀ» È®´ëÇÏ¿© ¾Ï Ä¡·á¿¡ÀÇ µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä »ç¿ëÀÚ¿Í ±×µéÀÇ ´ÏÁî´Â?

Á¾¾ç ÀýÁ¦¼ú ±â¼úÀÇ ÁÖ¿ä »ç¿ëÀÚ´Â Á¾¾ç Àü¹®ÀÇ, ÁßÀçÀû ¹æ»ç¼± Àü¹®ÀÇ, ¿Ü°úÀÇ»ç µîÀÌ ÀÖ½À´Ï´Ù. Á¾¾ç Àü¹®ÀÇ´Â Á¾¾ç ÀýÁ¦¼úÀ» ¾Ï Ä¡·áÀÇ ´ÙÇÐÁ¦Àû Á¢±ÙÀÇ ÀÏȯÀ¸·Î »ç¿ëÇϸç, ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 Á¾¾çÀ» Á¤È®Çϰí È¿°úÀûÀ¸·Î ÆÄ±«ÇÒ ¼ö ÀÖ´Â ±â¼úÀ» ã°í ÀÖ½À´Ï´Ù. ÁßÀçÀû ¹æ»ç¼± Àü¹®ÀÇ´Â ¿µ»ó À¯µµ ¼ÒÀÛ¼úÀ» ¼öÇàÇϱâ À§ÇØ Á¤È®ÇÑ Å¸°ÙÆÃ°ú ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» Á¦°øÇϴ ÷´Ü ¿µ»ó Áø´Ü ¹× ¼ÒÀÛ ½Ã½ºÅÛÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ¿Ü°ú ÀÇ»çµéÀº ¿Ü°úÀû ÀýÁ¦¼úÀ» º¸Á¶Çϰųª ¿Ü°úÀû Á¢±ÙÀÌ ¾î·Á¿î Á¾¾çÀ» Ä¡·áÇϱâ À§ÇØ ½Å·ÚÇÒ ¼ö ÀÖ°í ´ÙÀç´Ù´ÉÇÑ ÀýÁ¦¼ú Àåºñ¸¦ ÇÊ¿ä·Î ÇÕ´Ï´Ù. °¢ »ç¿ëÀÚ ±×·ìÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷±â À§ÇØ ³ôÀº Á¤È®µµ, ¾ÈÀü¼º, À¯È¿¼ºÀ» Á¦°øÇÏ´Â Á¾¾ç ÀýÁ¦ ±â¼úÀ» ³ôÀÌ Æò°¡Çϰí ÀÖ½À´Ï´Ù.

Á¾¾ç ÀýÁ¦ ±â¼ú ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

Á¾¾ç ÀýÁ¦ ±â¼ú ½ÃÀåÀÇ ¼ºÀåÀº ¾Ï ¹ßº´·ü Áõ°¡, ÀýÁ¦ ±â¼úÀÇ ¹ßÀü, ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÌ°í ´ú ħ½ÀÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Á¾¾ç ÀýÁ¦ ±â¼úÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿µ»ó À¯µµ, ¿¡³ÊÁö Àü´Þ ½Ã½ºÅÛ, ±â±â ¼³°è °³¼± µî ÀýÁ¦ ±â¼úÀÇ ¹ßÀüÀº ÀýÁ¦¼úÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ȸº¹ ½Ã°£ ´ÜÃà, ÇÕº´Áõ ¹ß»ý·ü °¨¼Ò, ȯÀÚ ÆíÀǼº Çâ»ó µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 Á¾¾ç ÀýÁ¦¼úÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áÁø°ú ȯÀÚµé »çÀÌ¿¡¼­ ÀýÁ¦¼ú¿¡ ´ëÇÑ Àνİú ¼ö¿ëµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó Á¾¾ç ÀýÁ¦¼ú ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(46°³»ç)

  • AngioDynamics, Inc.
  • Boston Scientific Corporation
  • BTG International Ltd.
  • EDAP TMS SA
  • Galil Medical Ltd.
  • HealthTronics, Inc.
  • Medtronic PLC
  • Mermaid Medical A/S
  • Misonix, Inc.
  • NeuWave Medical, Inc.
  • SonaCare Medical LLC

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå °³¿ä
  • ÁÖ¿ä ±â¾÷
  • ½ÃÀå µ¿Çâ°ú ¼ºÀå ÃËÁø¿äÀÎ
  • ¼¼°è ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ºÐ¼®

  • ¹Ì±¹
  • ij³ª´Ù
  • ÀϺ»
  • Áß±¹
  • À¯·´
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ¿µ±¹
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ±âŸ Áö¿ª

Á¦4Àå °æÀï

ksm 24.09.05

Global Tumor Ablation Technologies Market to Reach US$3.8 Billion by 2030

The global market for Tumor Ablation Technologies estimated at US$1.6 Billion in the year 2023, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2023-2030. Radiofrequency Ablation, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Microwave Ablation segment is estimated at 14.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$429.6 Million While China is Forecast to Grow at 12.3% CAGR

The Tumor Ablation Technologies market in the U.S. is estimated at US$429.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$574.2 Million by the year 2030 trailing a CAGR of 12.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.0% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.5% CAGR.

Global Tumor Ablation Technologies Market - Key Trends & Drivers Summarized

What Are Tumor Ablation Technologies and Why Are They Crucial?

Tumor ablation technologies are minimally invasive procedures used to destroy cancerous tissues by applying extreme heat or cold, electrical energy, or chemical agents. These technologies include radiofrequency ablation (RFA), microwave ablation, cryoablation, and chemical ablation. Tumor ablation is crucial for treating localized tumors in organs such as the liver, kidney, lung, and bone, offering an alternative to traditional surgical methods. These technologies provide significant benefits, including reduced recovery time, minimal invasiveness, and the ability to target tumors with precision. Tumor ablation is particularly valuable for patients who are not candidates for surgery or those with tumors in difficult-to-reach locations.

How Have Technological Advances Shaped the Market?

Technological advances have significantly influenced the development and application of tumor ablation technologies. Innovations in imaging techniques, such as ultrasound, CT, and MRI, have improved the accuracy and guidance of ablation procedures, allowing for more precise targeting of tumors. The development of advanced ablation devices with enhanced energy delivery systems has increased the efficacy and safety of ablation treatments, reducing the risk of complications and improving patient outcomes. Advancements in catheter and probe design have improved the ease of use and versatility of ablation technologies, enabling their use in a wider range of clinical settings. Additionally, the integration of real-time monitoring and feedback systems has enhanced the control and effectiveness of ablation procedures. These technological advancements have expanded the applications and effectiveness of tumor ablation technologies, driving their adoption in cancer treatment.

Who Are the Key Users and What Are Their Needs?

The key users of tumor ablation technologies include oncologists, interventional radiologists, and surgeons. Oncologists use tumor ablation as part of a multidisciplinary approach to cancer treatment, seeking technologies that offer precise and effective tumor destruction with minimal side effects. Interventional radiologists perform image-guided ablation procedures, requiring advanced imaging and ablation systems that provide accurate targeting and real-time monitoring. Surgeons utilize ablation technologies as an adjunct to surgical resection or for treating tumors that are difficult to access surgically, demanding reliable and versatile ablation devices. Each user group values tumor ablation technologies that offer high precision, safety, and effectiveness to improve patient outcomes and expand treatment options.

What Is Driving Growth in the Tumor Ablation Technologies Market?

The growth in the tumor ablation technologies market is driven by several factors, including the increasing prevalence of cancer, advancements in ablation technologies, and the rising demand for minimally invasive treatments. The growing incidence of cancer worldwide has increased the need for effective and less invasive treatment options, driving the adoption of tumor ablation technologies. Advancements in ablation technologies, including improvements in imaging guidance, energy delivery systems, and device design, have enhanced the safety and efficacy of ablation procedures, supporting market growth. The rising demand for minimally invasive treatments, driven by the benefits of reduced recovery time, lower complication rates, and improved patient comfort, has further fueled the adoption of tumor ablation technologies. Additionally, increasing awareness and acceptance of ablation treatments among healthcare professionals and patients have supported the growth of the tumor ablation technologies market.

Select Competitors (Total 46 Featured) -

  • AngioDynamics, Inc.
  • Boston Scientific Corporation
  • BTG International Ltd.
  • EDAP TMS SA
  • Galil Medical Ltd.
  • HealthTronics, Inc.
  • Medtronic PLC
  • Mermaid Medical A/S
  • Misonix, Inc.
  • NeuWave Medical, Inc.
  • SonaCare Medical LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tumor Ablation Technologies - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Cancer
    • Advancements in Imaging and Guidance Systems
    • Growth in Minimally Invasive Treatment Options
    • Impact of Technological Innovations in Ablation Devices
    • Development of Combination Therapies
    • Rising Adoption of Outpatient Procedures
    • Expansion of Radiofrequency and Microwave Ablation
    • Innovations in Cryoablation and Laser Ablation Technologies
    • Increasing Focus on Patient Safety and Treatment Efficacy
    • Growth in Clinical Research and Trials
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Tumor Ablation Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Tumor Ablation Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Radiofrequency Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Radiofrequency Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Radiofrequency Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Microwave Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Microwave Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Microwave Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cryoablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Cryoablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Cryoablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 25: World Tumor Ablation Technologies Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Irreversible Electroporation Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Irreversible Electroporation Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Irreversible Electroporation Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Kidney Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Kidney Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Kidney Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tumor Ablation Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Tumor Ablation Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Tumor Ablation Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Tumor Ablation Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Tumor Ablation Technologies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Tumor Ablation Technologies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Tumor Ablation Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Tumor Ablation Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Tumor Ablation Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Tumor Ablation Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of World Historic Review for Tumor Ablation Technologies by Technology - Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of World 16-Year Perspective for Tumor Ablation Technologies by Technology - Percentage Breakdown of Value Sales for Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 110: Rest of World Recent Past, Current & Future Analysis for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of World Historic Review for Tumor Ablation Technologies by Application - Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of World 16-Year Perspective for Tumor Ablation Technologies by Application - Percentage Breakdown of Value Sales for Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦